213 related articles for article (PubMed ID: 32440718)
1. ASO Author Reflections: Active Surveillance for Ductal Carcinoma In Situ (DCIS).
Oseni TO; Bahl M
Ann Surg Oncol; 2020 Oct; 27(11):4466-4467. PubMed ID: 32440718
[No Abstract] [Full Text] [Related]
2. Ductal carcinoma in situ (DCIS) of the breast--a therapeutic dilemma.
van Dongen JA; Bartelink H; Fentiman IS; Peterse JL
Eur J Surg Oncol; 1987 Apr; 13(2):123-5. PubMed ID: 3030824
[TBL] [Abstract][Full Text] [Related]
3. Is there a low-grade precursor pathway in breast cancer?
King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
[TBL] [Abstract][Full Text] [Related]
4. The Landmark Series-Ductal Carcinoma in Situ: The Evolution of Treatment.
Nash AL; Hwang ES
Ann Surg Oncol; 2023 Jun; 30(6):3206-3214. PubMed ID: 37024766
[TBL] [Abstract][Full Text] [Related]
5. Advances and controversies in management of breast ductal carcinoma in situ (DCIS).
Farante G; Toesca A; Magnoni F; Lissidini G; Vila J; Mastropasqua M; Viale G; Penco S; Cassano E; Lazzeroni M; Bonanni B; Leonardi MC; Ripoll-Orts F; Curigliano G; Orecchia R; Galimberti V; Veronesi P
Eur J Surg Oncol; 2022 Apr; 48(4):736-741. PubMed ID: 34772587
[TBL] [Abstract][Full Text] [Related]
6. ASO Author's Reflections: Are Genomic Assays Informing the Management of Ductal Carcinoma in situ as They Have for Invasive Breast Cancer?
Piltin MA; Boughey JC
Ann Surg Oncol; 2021 Aug; 28(8):4304-4305. PubMed ID: 33527230
[No Abstract] [Full Text] [Related]
7. Nonpalpable in situ ductal carcinoma of the breast. Predictors of multicentricity and microinvasion and implications for treatment.
Schwartz GF; Patchefsky AS; Finklestein SD; Sohn SH; Prestipino A; Feig SA; Singer JS
Arch Surg; 1989 Jan; 124(1):29-32. PubMed ID: 2535928
[TBL] [Abstract][Full Text] [Related]
8. Are There Alternative Strategies for the Local Management of Ductal Carcinoma in Situ?
Rosso KJ; Weiss A; Thompson AM
Surg Oncol Clin N Am; 2018 Jan; 27(1):69-80. PubMed ID: 29132566
[TBL] [Abstract][Full Text] [Related]
9. The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS).
Hwang ES; Hyslop T; Lynch T; Frank E; Pinto D; Basila D; Collyar D; Bennett A; Kaplan C; Rosenberg S; Thompson A; Weiss A; Partridge A
BMJ Open; 2019 Mar; 9(3):e026797. PubMed ID: 30862637
[TBL] [Abstract][Full Text] [Related]
10. Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.
Gradishar WJ; Anderson BO; Balassanian R; Blair SL; Burstein HJ; Cyr A; Elias AD; Farrar WB; Forero A; Giordano SH; Goetz MP; Goldstein LJ; Isakoff SJ; Lyons J; Marcom PK; Mayer IA; McCormick B; Moran MS; O'Regan RM; Patel SA; Pierce LJ; Reed EC; Salerno KE; Schwartzberg LS; Sitapati A; Smith KL; Smith ML; Soliman H; Somlo G; Telli ML; Ward JH; Kumar R; Shead DA
J Natl Compr Canc Netw; 2018 Mar; 16(3):310-320. PubMed ID: 29523670
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive prognostic report of the Japanese Breast Cancer Society Registry in 2004.
Kinoshita T; Fukui N; Anan K; Iwamoto T; Niikura N; Kawai M; Hayashi N; Tsugawa K; Aogi K; Ishida T; Masuoka H; Masuda S; Iijima K; Nakamura S; Tokuda Y
Breast Cancer; 2016 Jan; 23(1):39-49. PubMed ID: 26446041
[No Abstract] [Full Text] [Related]
12. Boosting anti-HER2 CD4 T-helper responses in HER2 expressing ductal carcinoma in situ.
Nocera NF; Lee MC; Czerniecki BJ
Future Oncol; 2017 Jul; 13(17):1459-1462. PubMed ID: 28766964
[No Abstract] [Full Text] [Related]
13. Imaging Features of Patients Undergoing Active Surveillance for Ductal Carcinoma in Situ.
Grimm LJ; Ghate SV; Hwang ES; Soo MS
Acad Radiol; 2017 Nov; 24(11):1364-1371. PubMed ID: 28705686
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of the Less Is More Approach in Treating Low-Risk Ductal Carcinoma In Situ Diagnosed on Core Needle Biopsy: Ten-Year Review of Ductal Carcinoma In Situ Upgraded to Invasion at Surgery.
Podoll MB; Reisenbichler ES; Roland L; Bruner A; Mizuguchi S; Sanders MAG
Arch Pathol Lab Med; 2018 Sep; 142(9):1120-1126. PubMed ID: 29582675
[TBL] [Abstract][Full Text] [Related]
15. [Noninvasive breast carcinomas: anatomicopathological, diagnostic and therapeutic findings].
Calabrese L
Acta Biomed Ateneo Parmense; 1998; 69(3-4):113-21. PubMed ID: 10503071
[TBL] [Abstract][Full Text] [Related]
16. A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast.
Van Bockstal MR; Agahozo MC; Koppert LB; van Deurzen CHM
Int J Cancer; 2020 Mar; 146(5):1189-1197. PubMed ID: 31018242
[TBL] [Abstract][Full Text] [Related]
17. Surveillance, Epidemiology, and End Results program underestimates breast cancer-specific mortality after ductal carcinoma in situ diagnosis.
O'Keefe TJ; Wallace AM
Breast Cancer Res Treat; 2020 Aug; 182(3):761-762. PubMed ID: 32529407
[No Abstract] [Full Text] [Related]
18. Navigating treatment controversies for DCIS in the era of genomic profiling and active surveillance trials.
Kuerer HM
Eur J Surg Oncol; 2018 Apr; 44(4):386-387. PubMed ID: 29398321
[No Abstract] [Full Text] [Related]
19. Pathology and clinical evolution of ductal carcinoma in situ (DCIS) of the breast.
Page DL; Lagios MD
Cancer Lett; 1994 Oct; 86(1):1-4. PubMed ID: 7954344
[TBL] [Abstract][Full Text] [Related]
20. Influence of ductal carcinoma in situ on the outcome of invasive breast cancer. A prospective cohort study.
Lopez Gordo S; Blanch Falp J; Lopez-Gordo E; Just Roig E; Encinas Mendez J; Seco Calvo J
Int J Surg; 2019 Mar; 63():98-106. PubMed ID: 30738200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
